The Reserve Bank of India (RBI), through a circular dated 17 March 2026, mandated the use of a Unique Transaction Identifier (UTI) for all over-the-counter (OTC) derivative transactions reported to the CCIL Trade Repository. The directive covers rupee interest rate derivatives, forward contracts in government securities, foreign currency derivatives, foreign currency interest rate derivatives, and credit derivatives.
Background
The UTI is a globally recognised data element designed to enable comprehensive monitoring and risk assessment of OTC derivative markets. The concept originates from recommendations by the Financial Stability Board (FSB) and the Committee on Payments and Market Infrastructures (CPMI), which advocated standardised identifiers to improve transparency in derivative markets following the 2008 global financial crisis.
In India, OTC derivative transactions are reported to the Trade Repository maintained by the Clearing Corporation of India Limited (CCIL). Prior to this circular, the reporting framework did not uniformly require a standardised unique identifier for each transaction, potentially limiting the ability of regulators to aggregate and analyse derivative exposures across counterparties and product types.
Key Provisions
The RBI circular establishes the following requirements:
Mandatory UTI assignment: Every OTC derivative transaction must be assigned a Unique Transaction Identifier at the point of execution. The UTI must accompany all reporting submissions to the CCIL Trade Repository.
Product coverage: The mandate applies to five categories of OTC derivatives:
- Rupee interest rate derivatives
- Forward contracts in government securities
- Foreign currency derivatives
- Foreign currency interest rate derivatives
- Credit derivatives
Reporting obligation: All regulated entities that are counterparties to OTC derivative transactions must ensure that the UTI is included in transaction reports submitted to CCIL.
Global alignment: The UTI framework aligns Indian derivative reporting standards with international norms established under the ISO 23897 standard for unique transaction identifiers in OTC derivatives.
Implications for Practitioners
Banks, non-banking financial companies, and other regulated entities active in OTC derivative markets must update their trade capture and reporting systems to generate and transmit UTIs in compliance with the circular. Technology and operations teams at financial institutions should prioritise system upgrades to ensure UTI generation is embedded within trade execution workflows.
For compliance functions at banks and financial institutions, the circular introduces an additional reporting parameter that must be validated before submission to CCIL. Incomplete or inaccurate UTI reporting could attract regulatory scrutiny, and institutions should implement automated validation checks to prevent reporting errors.
Legal counsel advising on derivative documentation, including ISDA Master Agreements and their Indian law equivalents, should consider whether existing contractual frameworks adequately address the obligation of counterparties to cooperate in generating and sharing UTIs. Where bilateral agreements govern reporting responsibilities, amendments may be necessary to reflect the new requirement.
The broader significance of this circular lies in its enhancement of the RBI's capacity for systemic risk monitoring. A standardised identifier across all OTC derivative transactions enables regulators to trace exposures, detect concentration risks, and respond more effectively to market stress events.